Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Non-Current Assets (2016 - 2026)

Insight Molecular Diagnostics' Non-Current Assets history spans 7 years, with the latest figure at $9.2 million for Q4 2025.

  • On a quarterly basis, Non-Current Assets rose 46.27% to $9.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $9.2 million, a 46.27% increase, with the full-year FY2025 number at $9.2 million, up 46.27% from a year prior.
  • Non-Current Assets hit $9.2 million in Q4 2025 for Insight Molecular Diagnostics, up from $6.5 million in the prior quarter.
  • Over the last five years, Non-Current Assets for IMDX hit a ceiling of $127.4 million in Q2 2021 and a floor of $5.4 million in Q4 2023.
  • Historically, Non-Current Assets has averaged $65.4 million across 5 years, with a median of $66.0 million in 2021.
  • Biggest five-year swings in Non-Current Assets: skyrocketed 183.02% in 2021 and later tumbled 92.71% in 2023.
  • Tracing IMDX's Non-Current Assets over 5 years: stood at $120.4 million in 2021, then tumbled by 38.09% to $74.6 million in 2022, then tumbled by 92.71% to $5.4 million in 2023, then increased by 16.34% to $6.3 million in 2024, then soared by 46.27% to $9.2 million in 2025.
  • Business Quant data shows Non-Current Assets for IMDX at $9.2 million in Q4 2025, $6.5 million in Q3 2025, and $6.7 million in Q2 2025.